BRAF V600E Metastatic Colorectal Cancer: Perspective from a Patient, a Caregiver, and an Oncologist
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
BRAF V600E Metastatic Colorectal Cancer: Perspective from a Patient, a Caregiver, and an Oncologist ; volume:40 ; number:8 ; day:14 ; month:6 ; year:2023 ; pages:3281-3290 ; date:8.2023
Advances in therapy ; 40, Heft 8 (14.6.2023), 3281-3290, 8.2023
- Urheber
-
Gourdin, Guillaume
Chotel, Laure
Fouchardière, Christelle de la
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-023-02552-8
- URN
-
urn:nbn:de:101:1-2023101308092459005963
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:53 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Gourdin, Guillaume
- Chotel, Laure
- Fouchardière, Christelle de la
- SpringerLink (Online service)
Ähnliche Objekte (12)
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer
Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial
BRAF Non-V600E Mutated Metastatic Colorectal Cancer in a Young Patient: Discussion from a Case Report
Nachweis der BRAF-V600E-Mutation beim metastasierten kolorektalen Karzinom : : ein QuIP-Ringversuch = Detection of BRAF V600E mutation in metastatic colorectal carcinoma : a QuIP round robin test
BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer
Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas
BRAF V600E -mutated serrated colorectal neoplasia drives transcriptional activation of cholesterol metabolism
BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
BRAF V600E Metastatic Melanoma Journey: A Perspective from a Patient and his Oncologist
Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Prognostic factors of BRAF V600E colorectal cancer with liver metastases: a retrospective multicentric study
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer
Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial
BRAF Non-V600E Mutated Metastatic Colorectal Cancer in a Young Patient: Discussion from a Case Report
Nachweis der BRAF-V600E-Mutation beim metastasierten kolorektalen Karzinom : : ein QuIP-Ringversuch = Detection of BRAF V600E mutation in metastatic colorectal carcinoma : a QuIP round robin test
BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer
Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas
BRAF V600E -mutated serrated colorectal neoplasia drives transcriptional activation of cholesterol metabolism
BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
BRAF V600E Metastatic Melanoma Journey: A Perspective from a Patient and his Oncologist
Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Prognostic factors of BRAF V600E colorectal cancer with liver metastases: a retrospective multicentric study
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer
Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial
BRAF Non-V600E Mutated Metastatic Colorectal Cancer in a Young Patient: Discussion from a Case Report
Nachweis der BRAF-V600E-Mutation beim metastasierten kolorektalen Karzinom : : ein QuIP-Ringversuch = Detection of BRAF V600E mutation in metastatic colorectal carcinoma : a QuIP round robin test
BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer
Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas
BRAF V600E -mutated serrated colorectal neoplasia drives transcriptional activation of cholesterol metabolism
BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
BRAF V600E Metastatic Melanoma Journey: A Perspective from a Patient and his Oncologist
Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated